Operating profit before deduction of amortization: X4 Pharmaceuticals, Inc. (XFOR)
The implementation of robotic bioscreening accelerates the discovery of new molecules, which correlates with the dynamics of absolute EBITDA. The value of 0.00 reflects the metric's balance, confirming the business's resilience. The monopoly status of X4 Pharmaceuticals (XFOR) with the drug Xolremdi provides pricing power, while the defensive nature of the immunology sector makes demand independent of macroeconomic fluctuations.
X4 Pharmaceuticals, Inc. (XFOR) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Equity Ratio X4 Pharmaceuticals|XFOR - Long-Term Debt to Capital|Current Liabilities to Capital X4 Pharmaceuticals Inc.|XFOR - Company Total Debt|Debt to Book Value Ratio X4 Pharmaceuticals|XFOR - Company Long-Term Indebtedness|Company Current Liabilities X4 Pharmaceuticals|Quick Liquidity x4pharma.com
- earnings and multiples data:
XFOR - Profit After Tax|Projected Future Earnings X4 Pharmaceuticals|XFOR - Company Value to Net Income|Forward P/E Multiple x4pharma.com|XFOR - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization X4 Pharmaceuticals|XFOR - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months X4 Pharmaceuticals|XFOR - Net earnings per share for the last 12 months|Quarterly EPS earnings growth x4pharma.com|XFOR - Earnings growth in current year|Earnings growth forecast for next year X4 Pharmaceuticals
Fundamental company valuation:X4 Pharmaceuticals, Inc - XFOR
Investors are verifying the issuer's resilience through cash flow dynamics, utilizing multiples to assess the actual efficiency of capital management. An analysis of actual EBITDA allows for tracking the conversion of drug sales revenue against fixed R&D expenses, where the upward trend on the chart confirms the activation of operating leverage and the successful scaling of the X4 Pharmaceuticals (XFOR) business model during its transition to the commercial stage.
Competitor analysis
Operating income before deduction of amortization argenx BVBA (ARGX)|BNTX - Profit before payment of interest, taxes and amortization|Abivax S.A. (ABVX) - Operating profit before deduction of amortization|ADMA Biologics, Inc. (ADMA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Protagonist Therapeutics, Inc.|Operating profit before deduction of amortization IMVT|Operating profit EBITDA Kiniksa Corp|Profit before payment of interest, taxes and amortization Grifols, S.A. (GRFS)|adaptivebiotech.com - Operating profit before amortization|Operating profit EBITDA CLDX (Celldex Therapeutics, Inc.)|Aurinia Pharmaceuticals Inc (AUPH) - Profit before interest, taxes and amortization|BCRX: Operating profit before deduction of amortization|VERA (Vera Corp) - Operating profit before amortization|Operating profit before amortization Dianthus Therapeutics|Operating profit before deduction of amortization pharvaris.com|ABCL - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization TRML|PGEN - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA Pharming Corp (PHAR)|Income before deduction of interest, taxes and amortization Nektar Therapeutics|Operating profit EBITDA upstreambio.com UPB|Zenas Biopharma - Operating profit EBITDA|IMNM: Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization Gossamer Corp GOSS|KALV (KalVista Corp) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization SEPN|Operating profit EBITDA pieris.com|Operating profit EBITDA SVRA|Operating profit EBITDA Rigel Pharma (RIGL)|AnaptysBio Corp - Operating profit before deduction of amortization|Operating profit EBITDA Astria Corp ATXS|ENGN (enGene Holdings Inc.) - Profit before interest, taxes and amortization|RAPT Therapeutics Inc. (RAPT) - Operating profit before deduction of amortization|JBIO: Operating profit EBITDA|Operating profit before deduction of amortization Aclaris Therapeutics Inc.|Kyverna (KYTX) - Company profit before taxes, interest and amortization|Operating profit EBITDA Tiziana Life Sciences, Ltd.|CABA (Cabaletta Bio, Inc.) - Operating income before deduction of amortization|Operating profit EBITDA ventyxbio.com (VTYX)|Theratechnologies - Operating profit before deduction of amortization|Operating profit EBITDA Avalo Therapeutics, Inc. AVTX|Eledon - Operating profit EBITDA|AGEN: Profit before payment of interest, taxes and amortization|Climb Bio Inc (CLYM) - Profit before payment of interest, taxes and amortization|ZURA (Zura Bio Ltd) - Profit before payment of interest, taxes and amortization|ATYR: Operating income before deduction of amortization|Operating profit before deduction of amortization Adagene Corp (ADAG)|Operating profit before amortization ImageneBio Inc IMA|Operating profit EBITDA shattucklabs.com (STTK)|Equillium (EQ) - Profit before deduction of interest, taxes, depreciation and amortization|Connect Biopharma Holdings - Profit before payment of interest, taxes and amortization|IMUX (Immunic Inc) - Profit before interest, taxes and amortization|ATRA: Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization inflarx.de IFRX|ACET (Adicet Bio, Inc.) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization Celularity Inc CELU|Operating profit EBITDA inmunebio.com|Barinthus Biotherapeutics plc (BRNS) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA Kezar Life Sciences Inc. (KZR)|Operating profit EBITDA SABS (SAB Biotherapeutics, Inc)|Akari Therapeutics, Plc - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization Enlivex Therapeutics, Ltd. (ENLV)|QTTB: Profit before payment of interest, taxes and amortization|GOVX (GeoVax) - Operating profit before deduction of amortization|Edesa Biotech Inc (EDSA) - Operating profit EBITDA|IBIO (iBio Corp) - Operating profit EBITDA|Operating profit before deduction of amortization Carisma Tx (CARM)|XTL Biopharmaceuticals (XTLB) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA boltbio.com (BOLT)|Operating income before deduction of amortization HCWB|Aptevo Therapeutics, Inc. - Profit before payment of interest, taxes and amortization|AIM: Operating profit before deduction of amortization|ADTX: Profit before payment of interest, taxes and amortization|GRI (GRI Bio, Inc.) - Operating profit before deduction of amortization|Operating profit before deduction of amortization xortx.com|HIND (Vyome Holdings) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization REVB|Operating profit before amortization Indaptus INDP|Operating profit EBITDA BiondVax Pharmaceuticals (SCNI)|CALI: Profit before interest, taxes and amortization|AFMD - Operating profit before deduction of amortization|Allakos Therapeutics (ALLK) - Operating profit before amortization|HOOK (HOOKIPA Pharma Inc.) - Operating profit before amortization|IGMS (igmbio.com) - Operating profit before deduction of amortization|iTeos Pharma - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Ocean Biomedical, Inc.|tcbiopharm.com - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA THRD
